| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Phytohemagglutinins | 4 | 2018 | 15 | 2.41 | Why? |
| Antigens, Bacterial | 5 | 2018 | 330 | 1.50 | Why? |
| Lymphocyte Activation | 3 | 2020 | 2742 | 1.09 | Why? |
| Disseminated Intravascular Coagulation | 2 | 2020 | 994 | 0.87 | Why? |
| Receptors, Immunologic | 2 | 2017 | 555 | 0.83 | Why? |
| Fibrinolysin | 1 | 2020 | 80 | 0.82 | Why? |
| Mycobacterium tuberculosis | 4 | 2018 | 1164 | 0.81 | Why? |
| Fusobacteriaceae Infections | 1 | 2018 | 2 | 0.79 | Why? |
| Humeral Fractures | 1 | 2019 | 25 | 0.79 | Why? |
| Perianal Glands | 1 | 2018 | 2 | 0.79 | Why? |
| Leptotrichia | 1 | 2018 | 46 | 0.78 | Why? |
| Gram-Positive Cocci | 1 | 2018 | 20 | 0.75 | Why? |
| Syphilis Serodiagnosis | 1 | 2018 | 30 | 0.75 | Why? |
| Ionomycin | 1 | 2018 | 11 | 0.75 | Why? |
| Phorbol Esters | 1 | 2018 | 14 | 0.74 | Why? |
| Nontuberculous Mycobacteria | 1 | 2019 | 114 | 0.71 | Why? |
| Tuberculoma | 1 | 2017 | 6 | 0.70 | Why? |
| Ulcer | 1 | 2018 | 128 | 0.67 | Why? |
| Escherichia coli Infections | 2 | 2018 | 348 | 0.67 | Why? |
| Tuberculosis, Pulmonary | 2 | 2018 | 1171 | 0.65 | Why? |
| CD4-Positive T-Lymphocytes | 4 | 2020 | 4545 | 0.65 | Why? |
| Bacteremia | 3 | 2018 | 1372 | 0.64 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2018 | 1380 | 0.64 | Why? |
| Solitary Pulmonary Nodule | 1 | 2017 | 83 | 0.62 | Why? |
| Immunoenzyme Techniques | 1 | 2018 | 448 | 0.62 | Why? |
| Klebsiella pneumoniae | 4 | 2018 | 658 | 0.60 | Why? |
| Klebsiella Infections | 2 | 2017 | 466 | 0.57 | Why? |
| Vancomycin Resistance | 1 | 2014 | 55 | 0.57 | Why? |
| Molecular Diagnostic Techniques | 3 | 2020 | 4239 | 0.55 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2018 | 323 | 0.55 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 214 | 0.54 | Why? |
| Syphilis | 1 | 2018 | 318 | 0.54 | Why? |
| Prothrombin Time | 3 | 2020 | 434 | 0.53 | Why? |
| Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 284 | 0.53 | Why? |
| beta-Lactamases | 2 | 2018 | 759 | 0.52 | Why? |
| Biomarkers | 8 | 2020 | 23361 | 0.52 | Why? |
| Surgical Wound Infection | 1 | 2019 | 501 | 0.51 | Why? |
| Tuberculosis | 4 | 2018 | 2895 | 0.51 | Why? |
| Colon | 1 | 2018 | 669 | 0.50 | Why? |
| Lymphocyte Subsets | 1 | 2020 | 987 | 0.50 | Why? |
| Interferon-gamma | 3 | 2020 | 2711 | 0.50 | Why? |
| Staphylococcus aureus | 3 | 2018 | 844 | 0.49 | Why? |
| Oropharynx | 2 | 2020 | 1581 | 0.48 | Why? |
| Sepsis | 2 | 2021 | 3517 | 0.47 | Why? |
| Clostridium Infections | 1 | 2019 | 595 | 0.45 | Why? |
| China | 25 | 2021 | 50654 | 0.44 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.42 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2020 | 2483 | 0.41 | Why? |
| Hepatitis B e Antigens | 1 | 2010 | 99 | 0.39 | Why? |
| Sputum | 1 | 2018 | 1720 | 0.39 | Why? |
| Microbial Sensitivity Tests | 8 | 2019 | 2886 | 0.39 | Why? |
| Crohn Disease | 1 | 2018 | 959 | 0.38 | Why? |
| Hepatitis B Antibodies | 1 | 2010 | 142 | 0.38 | Why? |
| Immunoassay | 2 | 2018 | 4485 | 0.37 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.37 | Why? |
| Partial Thromboplastin Time | 2 | 2020 | 436 | 0.36 | Why? |
| Clinical Laboratory Techniques | 6 | 2020 | 23402 | 0.35 | Why? |
| Lymphocytes | 3 | 2020 | 3056 | 0.35 | Why? |
| Hepatitis B Surface Antigens | 1 | 2010 | 305 | 0.35 | Why? |
| ROC Curve | 6 | 2021 | 6024 | 0.34 | Why? |
| Blood Coagulation | 2 | 2020 | 2768 | 0.34 | Why? |
| Multiple Organ Failure | 1 | 2017 | 1724 | 0.33 | Why? |
| Pseudomonas Infections | 1 | 2011 | 425 | 0.32 | Why? |
| Drug Resistance, Bacterial | 4 | 2019 | 1414 | 0.32 | Why? |
| Anti-Bacterial Agents | 9 | 2019 | 10083 | 0.32 | Why? |
| Betacoronavirus | 13 | 2020 | 204454 | 0.32 | Why? |
| Pseudomonas aeruginosa | 1 | 2011 | 652 | 0.32 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 2 | 2017 | 78 | 0.31 | Why? |
| Escherichia coli | 5 | 2019 | 1547 | 0.31 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2020 | 5837 | 0.31 | Why? |
| Pneumonia, Viral | 14 | 2020 | 243684 | 0.31 | Why? |
| Coronavirus Infections | 14 | 2020 | 253789 | 0.30 | Why? |
| Diarrhea | 1 | 2018 | 2743 | 0.30 | Why? |
| Male | 36 | 2021 | 367725 | 0.29 | Why? |
| Staphylococcal Infections | 1 | 2014 | 1099 | 0.29 | Why? |
| Female | 35 | 2021 | 380317 | 0.28 | Why? |
| Middle Aged | 29 | 2021 | 270681 | 0.27 | Why? |
| DNA, Bacterial | 2 | 2019 | 835 | 0.27 | Why? |
| Lymphocyte Count | 3 | 2020 | 4758 | 0.27 | Why? |
| Models, Biological | 2 | 2020 | 4907 | 0.26 | Why? |
| Blood Coagulation Tests | 2 | 2020 | 855 | 0.25 | Why? |
| Fibrin Fibrinogen Degradation Products | 4 | 2020 | 5993 | 0.25 | Why? |
| Aged | 24 | 2021 | 215776 | 0.25 | Why? |
| Gram-Negative Bacteria | 2 | 2018 | 473 | 0.25 | Why? |
| Membrane Glycoproteins | 1 | 2011 | 2273 | 0.24 | Why? |
| Aspartate Aminotransferases | 2 | 2020 | 1394 | 0.24 | Why? |
| Signal Transduction | 2 | 2017 | 7207 | 0.24 | Why? |
| Humans | 54 | 2021 | 930598 | 0.23 | Why? |
| Adult | 26 | 2021 | 244371 | 0.23 | Why? |
| Urinary Tract Infections | 2 | 2018 | 534 | 0.23 | Why? |
| Anticoagulants | 2 | 2020 | 9563 | 0.23 | Why? |
| Imipenem | 2 | 2018 | 57 | 0.23 | Why? |
| Aged, 80 and over | 11 | 2020 | 88759 | 0.23 | Why? |
| Prognosis | 7 | 2021 | 32490 | 0.22 | Why? |
| Hepatitis B | 1 | 2010 | 888 | 0.22 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.22 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.22 | Why? |
| L-Lactate Dehydrogenase | 2 | 2020 | 1995 | 0.22 | Why? |
| Latent Tuberculosis | 2 | 2017 | 324 | 0.22 | Why? |
| Intraabdominal Infections | 2 | 2018 | 90 | 0.21 | Why? |
| Infant | 7 | 2020 | 30274 | 0.21 | Why? |
| gamma-Glutamyltransferase | 1 | 2020 | 101 | 0.21 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.20 | Why? |
| Leukocyte Count | 2 | 2020 | 3178 | 0.20 | Why? |
| Receptors, Interleukin-2 | 1 | 2020 | 115 | 0.20 | Why? |
| Inflammation Mediators | 1 | 2011 | 2654 | 0.20 | Why? |
| Young Adult | 13 | 2020 | 93724 | 0.20 | Why? |
| Calgranulin A | 1 | 2020 | 74 | 0.20 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.20 | Why? |
| Calgranulin B | 1 | 2020 | 144 | 0.20 | Why? |
| CD4-CD8 Ratio | 1 | 2020 | 235 | 0.20 | Why? |
| DNA Gyrase | 1 | 2019 | 30 | 0.20 | Why? |
| Ribotyping | 1 | 2019 | 54 | 0.20 | Why? |
| Eye, Artificial | 1 | 2018 | 2 | 0.19 | Why? |
| Tuberculosis, Gastrointestinal | 1 | 2018 | 9 | 0.19 | Why? |
| beta-Lactams | 2 | 2018 | 210 | 0.19 | Why? |
| Amikacin | 1 | 2019 | 62 | 0.19 | Why? |
| Alkaline Phosphatase | 1 | 2020 | 257 | 0.19 | Why? |
| Retrospective Studies | 12 | 2021 | 105322 | 0.19 | Why? |
| Receptors, CXCR5 | 1 | 2018 | 35 | 0.19 | Why? |
| Killer Cells, Natural | 2 | 2020 | 2093 | 0.19 | Why? |
| Mining | 1 | 2018 | 32 | 0.19 | Why? |
| Enteropathogenic Escherichia coli | 1 | 2018 | 11 | 0.19 | Why? |
| Platelet Count | 3 | 2020 | 1381 | 0.19 | Why? |
| Factor XIII | 1 | 2017 | 13 | 0.18 | Why? |
| Polymerase Chain Reaction | 3 | 2019 | 6740 | 0.18 | Why? |
| Levofloxacin | 1 | 2019 | 115 | 0.18 | Why? |
| Treponema pallidum | 1 | 2018 | 42 | 0.18 | Why? |
| Diagnostic Tests, Routine | 2 | 2020 | 2643 | 0.18 | Why? |
| Infant, Newborn | 5 | 2020 | 23105 | 0.18 | Why? |
| Serotyping | 1 | 2018 | 154 | 0.18 | Why? |
| Bacteria, Aerobic | 1 | 2017 | 5 | 0.18 | Why? |
| Soybean Oil | 1 | 2017 | 6 | 0.18 | Why? |
| Mice, Inbred MRL lpr | 1 | 2017 | 9 | 0.18 | Why? |
| Blotting, Southern | 1 | 2017 | 18 | 0.17 | Why? |
| Conjugation, Genetic | 1 | 2017 | 12 | 0.17 | Why? |
| Ophthalmic Solutions | 1 | 2018 | 136 | 0.17 | Why? |
| HLA-DR Antigens | 1 | 2020 | 563 | 0.17 | Why? |
| Child, Preschool | 7 | 2020 | 36283 | 0.17 | Why? |
| Fracture Fixation, Internal | 1 | 2019 | 188 | 0.17 | Why? |
| Gene Transfer, Horizontal | 1 | 2017 | 64 | 0.17 | Why? |
| Candidiasis, Invasive | 1 | 2018 | 107 | 0.17 | Why? |
| Pregnancy Complications, Hematologic | 1 | 2018 | 114 | 0.16 | Why? |
| Metals, Heavy | 1 | 2018 | 147 | 0.16 | Why? |
| Azoles | 1 | 2018 | 185 | 0.16 | Why? |
| Biopsy, Needle | 1 | 2017 | 303 | 0.15 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.15 | Why? |
| Viral Regulatory and Accessory Proteins | 1 | 2021 | 482 | 0.15 | Why? |
| Rivers | 1 | 2018 | 304 | 0.15 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.15 | Why? |
| Adolescent | 9 | 2020 | 86841 | 0.15 | Why? |
| Protein Interaction Mapping | 1 | 2018 | 487 | 0.15 | Why? |
| Interferon-gamma Release Tests | 1 | 2018 | 253 | 0.15 | Why? |
| Diagnosis, Differential | 3 | 2020 | 7220 | 0.15 | Why? |
| Fibrinolysis | 1 | 2020 | 521 | 0.15 | Why? |
| Mycobacterium | 1 | 2017 | 143 | 0.15 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.14 | Why? |
| Phospholipids | 1 | 2017 | 202 | 0.14 | Why? |
| ADAMTS13 Protein | 1 | 2018 | 363 | 0.14 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.14 | Why? |
| Troponin T | 1 | 2020 | 771 | 0.14 | Why? |
| Methotrexate | 1 | 2018 | 471 | 0.14 | Why? |
| Face | 1 | 2018 | 301 | 0.14 | Why? |
| Abdomen | 1 | 2017 | 424 | 0.14 | Why? |
| Peptide Fragments | 2 | 2020 | 2075 | 0.13 | Why? |
| Interleukin-8 | 1 | 2020 | 964 | 0.13 | Why? |
| Eye | 1 | 2018 | 374 | 0.13 | Why? |
| Reproducibility of Results | 3 | 2020 | 11304 | 0.13 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 449 | 0.13 | Why? |
| Genome-Wide Association Study | 1 | 2021 | 1648 | 0.13 | Why? |
| Neutrophils | 4 | 2021 | 5476 | 0.13 | Why? |
| Sensitivity and Specificity | 5 | 2020 | 22971 | 0.13 | Why? |
| Candida | 1 | 2018 | 425 | 0.13 | Why? |
| Reference Standards | 1 | 2018 | 1163 | 0.13 | Why? |
| Interleukin-10 | 1 | 2020 | 1409 | 0.13 | Why? |
| Viremia | 1 | 2020 | 1020 | 0.13 | Why? |
| Natriuretic Peptide, Brain | 1 | 2020 | 1215 | 0.12 | Why? |
| Water Pollutants, Chemical | 1 | 2018 | 410 | 0.12 | Why? |
| DNA | 1 | 2018 | 778 | 0.12 | Why? |
| Macrophages, Peritoneal | 1 | 2011 | 38 | 0.12 | Why? |
| B7-2 Antigen | 1 | 2011 | 56 | 0.12 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.12 | Why? |
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2011 | 40 | 0.11 | Why? |
| Pandemics | 14 | 2020 | 389249 | 0.11 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2017 | 398 | 0.11 | Why? |
| Case-Control Studies | 3 | 2020 | 17671 | 0.11 | Why? |
| T-Lymphocytes | 2 | 2020 | 6670 | 0.11 | Why? |
| Dendritic Cells | 1 | 2020 | 1330 | 0.11 | Why? |
| CD40 Antigens | 1 | 2011 | 118 | 0.11 | Why? |
| Thrombelastography | 1 | 2017 | 627 | 0.11 | Why? |
| Ferritins | 1 | 2020 | 2055 | 0.11 | Why? |
| Erythrocytes | 1 | 2017 | 617 | 0.11 | Why? |
| Antitubercular Agents | 1 | 2018 | 775 | 0.11 | Why? |
| Immunoglobulin G | 5 | 2021 | 21571 | 0.11 | Why? |
| Prospective Studies | 5 | 2020 | 43301 | 0.11 | Why? |
| Follow-Up Studies | 3 | 2020 | 17020 | 0.11 | Why? |
| Proteins | 1 | 2018 | 921 | 0.10 | Why? |
| Shock, Septic | 1 | 2020 | 1313 | 0.10 | Why? |
| Bacterial Proteins | 1 | 2019 | 1318 | 0.10 | Why? |
| Child | 7 | 2020 | 70012 | 0.10 | Why? |
| Phagocytosis | 1 | 2011 | 409 | 0.10 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.10 | Why? |
| Peritonitis | 1 | 2011 | 217 | 0.10 | Why? |
| Chemokine CCL2 | 1 | 2011 | 389 | 0.10 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.10 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.09 | Why? |
| Cells, Cultured | 2 | 2017 | 5835 | 0.09 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.09 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.09 | Why? |
| Carrier State | 1 | 2020 | 2100 | 0.09 | Why? |
| Immunity | 1 | 2020 | 2651 | 0.09 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.09 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.08 | Why? |
| Automation | 1 | 2010 | 429 | 0.08 | Why? |
| Urokinase-Type Plasminogen Activator | 1 | 2007 | 62 | 0.08 | Why? |
| Plasminogen | 1 | 2007 | 58 | 0.08 | Why? |
| Recombinant Fusion Proteins | 1 | 2011 | 919 | 0.08 | Why? |
| Mice, Inbred BALB C | 2 | 2021 | 5814 | 0.08 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.08 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.08 | Why? |
| Interleukin-1beta | 1 | 2011 | 992 | 0.08 | Why? |
| Environmental Monitoring | 1 | 2018 | 3143 | 0.08 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.08 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.07 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.07 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.07 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Leukocytes | 1 | 2011 | 1046 | 0.07 | Why? |
| Machine Learning | 1 | 2021 | 4395 | 0.07 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.07 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.07 | Why? |
| Leukocytes, Mononuclear | 1 | 2013 | 2115 | 0.07 | Why? |
| Animals | 4 | 2021 | 78931 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.06 | Why? |
| Protein Engineering | 1 | 2007 | 536 | 0.06 | Why? |
| Phylogeny | 2 | 2020 | 13341 | 0.06 | Why? |
| Viral Nonstructural Proteins | 1 | 2021 | 4810 | 0.06 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.06 | Why? |
| Disease Models, Animal | 2 | 2021 | 10998 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3832 | 0.06 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.06 | Why? |
| Hepatitis B virus | 1 | 2010 | 882 | 0.06 | Why? |
| Community-Acquired Infections | 2 | 2017 | 2328 | 0.06 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.06 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.06 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Introns | 1 | 2021 | 112 | 0.06 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.06 | Why? |
| Asthma | 1 | 2020 | 4383 | 0.06 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.06 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.05 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.05 | Why? |
| Blood Platelets | 1 | 2011 | 1704 | 0.05 | Why? |
| Receptors, Virus | 1 | 2017 | 5659 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Cross Infection | 2 | 2018 | 8675 | 0.05 | Why? |
| Tibet | 1 | 2018 | 80 | 0.05 | Why? |
| Mycological Typing Techniques | 1 | 2018 | 38 | 0.05 | Why? |
| Protein Array Analysis | 1 | 2021 | 387 | 0.05 | Why? |
| Biophysical Phenomena | 1 | 2018 | 78 | 0.05 | Why? |
| Geologic Sediments | 1 | 2018 | 43 | 0.05 | Why? |
| Mutation | 1 | 2019 | 12376 | 0.05 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.04 | Why? |
| Kaolin | 1 | 2017 | 3 | 0.04 | Why? |
| Water Quality | 1 | 2018 | 93 | 0.04 | Why? |
| Pulmonary Embolism | 1 | 2017 | 4775 | 0.04 | Why? |
| HMGB1 Protein | 1 | 2020 | 223 | 0.04 | Why? |
| Mice | 2 | 2021 | 21357 | 0.04 | Why? |
| Emulsions | 1 | 2017 | 80 | 0.04 | Why? |
| Tomography, X-Ray Computed | 3 | 2020 | 25144 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Drug Resistance, Fungal | 1 | 2018 | 191 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.04 | Why? |
| Mean Platelet Volume | 1 | 2017 | 203 | 0.04 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.04 | Why? |
| Epitope Mapping | 1 | 2021 | 1240 | 0.04 | Why? |
| Cephalosporins | 1 | 2017 | 250 | 0.04 | Why? |
| Metabolomics | 1 | 2021 | 921 | 0.04 | Why? |
| Enterobacteriaceae | 1 | 2018 | 395 | 0.03 | Why? |
| Hyperlipidemias | 1 | 2017 | 290 | 0.03 | Why? |
| Hemolysis | 1 | 2017 | 283 | 0.03 | Why? |
| Thermodynamics | 1 | 2018 | 873 | 0.03 | Why? |
| Triglycerides | 1 | 2017 | 478 | 0.03 | Why? |
| Conservation of Natural Resources | 1 | 2018 | 520 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Interleukins | 1 | 2018 | 762 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 711 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| United States | 1 | 2018 | 46150 | 0.03 | Why? |
| Hemoglobins | 1 | 2017 | 958 | 0.03 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.02 | Why? |
| Genomics | 1 | 2021 | 3118 | 0.02 | Why? |
| Haemophilus influenzae | 1 | 2009 | 196 | 0.02 | Why? |
| Streptococcus pyogenes | 1 | 2009 | 118 | 0.02 | Why? |
| Respiratory Tract Infections | 1 | 2009 | 6817 | 0.02 | Why? |
| Peptides | 1 | 2021 | 2513 | 0.02 | Why? |
| Epitopes | 1 | 2021 | 4113 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2021 | 3607 | 0.02 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2021 | 4027 | 0.02 | Why? |
| Catalysis | 1 | 2007 | 253 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Streptococcus pneumoniae | 1 | 2009 | 827 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.01 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.01 | Why? |
| Recombinant Proteins | 1 | 2007 | 3786 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |